Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering and developing small molecule therapies. The firm's focus areas include hematologic disorders, oncology, and rare immune system conditions. Its commercialized product, Tavalisse (fostamatinib), is an oral spleen tyrosine kinase inhibitor approved for the treatment of chronic immune thrombocytopenia in adult patients. Rigel's robust pipeline features Fostamatinib, currently in Phase III clinical trials for several additional indications, including warm autoimmune hemolytic anemia, as well as separate studies for hospitalized COVID-19 patients and other COVID-19 applications. In its earlier development stages, the company is advancing R289, an oral interleukin receptor associated kinase 1/4 inhibitor undergoing Phase I clinical trials for autoimmune, inflammatory, and hematology-oncology diseases. Another promising compound, R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, has successfully completed Phase I clinical evaluation for autoimmune and inflammatory conditions. Rigel maintains several strategic collaborations to further its development efforts. These include research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a partnership with BerGenBio AS focusing on AXL inhibitors in oncology; and an agreement with Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies. The company also has a licensing and supply agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of Fostamatinib. Furthermore, Rigel has a significant collaboration and license agreement with Eli Lilly and Company to jointly develop and commercialize R552 for diverse therapeutic applications, including autoimmune and inflammatory disorders, alongside other non-central nervous system conditions. Founded in 1996, Rigel Pharmaceuticals, Inc. is headquartered in South San Francisco, California.
prnewswire.comRigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)prnewswire.comJun 16
prnewswire.comRigel to Present at the Jefferies Global Healthcare Conferenceprnewswire.comMay 27
prnewswire.comRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congressprnewswire.comMay 21
prnewswire.comRigel to Present at the 2026 RBC Capital Markets Global Healthcare Conferenceprnewswire.comMay 14
seekingalpha.comRigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcriptseekingalpha.comMay 12